The first-quarter earnings season for fiscal year 2026-27 has kicked off with a resounding success for major retail and pharmaceutical players, as Vishal Mega Mart and Novartis India both announced impressive financial scorecards. Driven by robust consumer demand, expanding market reach, and enhanced operational efficiencies, both companies registered substantial year-over-year double-digit growth across net profit, revenue, and core earnings parameters.
Vishal Mega Mart Posts 26% Jump in Net Profit on Strong Retail Demand
Retail giant Vishal Mega Mart delivered a power-packed performance for Q1FY27, reporting a stellar 26% year-on-year surge in consolidated net profit to ₹259 crore, compared to ₹206 crore during the corresponding period last year. The company’s top-line expansion was equally impressive, with revenue climbing 18.7% to ₹3,727 crore from ₹3,140 crore. Operational earnings matched this upward trajectory as EBITDA grew by 18.7% to reach ₹545 crore, up from ₹459.5 crore, while maintaining a rock-steady EBITDA margin of 14.6%, reflecting strong cost discipline and steady consumer spending.
Novartis India Delivers Robust Pharma Growth with Expanding Margins
On the pharmaceutical front, Novartis India presented an equally compelling financial report for the first quarter, showcasing strong profitability and margin expansion. The company’s net profit witnessed a healthy 16.6% increase, touching ₹32.2 crore compared to ₹27.6 crore in the same quarter a year ago. Total earnings grew by 18.6% to ₹103.8 crore, while EBITDA surged an impressive 28.2% to ₹34.9 crore. Benefiting from optimized operational efficiencies, Novartis India successfully expanded its EBITDA margin from 31.1% to a robust 33.6%, underscoring a highly profitable start to the new fiscal year.
Comments are closed.